With increasing drug development costs and complexity, meaningful clinical partnerships can help sponsors establish their most efficient and cost-effective processes.
In a concerted effort to partner with providers around the world, Quartesian has officially established a partnership with ILIKOS — a Cyprus-based provider of highly adaptive and tailored drug development solutions.
The unique partnership introduces Quartesian’s data management, biometrics, and pharmacovigilance solutions to European companies and the Middle East, Turkey, and Africa (META).
“Expanding our business in Europe has been a goal for Quartesian since our formation 17 years ago,” said Benjamin Jackson, Quartesian Co-founder and CEO. “[Quartesian is] excited about supporting ILIKOS in promoting clinical research in the META regions.”
Read ILIKOS’ full press release to learn more about our new strategic partnership.